Related Experiment Video

Updated: Aug 23, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

226

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Antoine N Saliba1, Scott H Kaufmann1,2,3, Eytan M Stein4

  • 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Blood Advances
|October 31, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

11.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Experiment Videos

Last Updated: Aug 23, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

226
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

11.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.

American journal of hematology·2026

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Leukemia·2026

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

American journal of hematology·2026

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

American journal of hematology·2026

NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

Blood·2026

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Cancer·2026

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

Blood advances·2026

A Synthetic, Small Molecule, Allosteric Inhibitor of Human Factor XIa for Thrombosis.

Blood advances·2026

Cumulative Stress Measured by Allostatic Load is Associated with Vaso-Occlusive Episodes in Sickle Cell Disease.

Blood advances·2026

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

Blood advances·2026

A hemoglobin >120g/L trends toward improved survival without increasing vascular events in ESA-treated MDS patients.

Blood advances·2026

Systematic Review and Meta-Analysis of Hypersensitivity Reactions after High-dose Intravenous Iron.

Blood advances·2026

Individualized breast cancer survival prediction in clinical practice: a SEER-derived interactive web tool integrating molecular and anatomical factors.

Journal of public health (Oxford, England)·2026

A Greek Real-World Experience With the Implementation of the EndoPredict Gene Signature in a Cohort of Pre-menopausal and Post-menopausal Patients With ER+/HER2- Breast Cancer.

Cureus·2026

A Myeloid-Specific Endogenous TRP1-CAR Knock-in Mouse Model for Melanoma-Targeted Immunotherapy.

ImmunoTargets and therapy·2026

Clinicopathological Features and Statistical Associations in Squamous Cell Carcinoma of the Lip.

Current health sciences journal·2026

Sex-Specific Predictive Value of Obesity-Related Indicators for Diabetic Kidney Disease in Type 2 Diabetes Mellitus.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026

Prognostic Value of FST and Relevance to Immune Infiltration in Head and Neck Squamous Cell Carcinoma.

World journal of otorhinolaryngology - head and neck surgery·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us